|
Showing 1 - 2 of
2 matches in All Departments
In 1997, Vagus Nerve Stimulation (VNS) therapy (Cyberonics,
Houston, Texas) was approved by the United States Food and Drug
Administration for the treatment of epilepsy refractory to
antiepileptic medications. In 2005, VNS received FDA approval for
treatment-resistant depression refractory to antidepressants, and
Cyberonics recently received FDA approval for the clinical study of
VNS for rapid cycling bipolar depression. Many researchers continue
to investigate the anxiolytic effects of VNS in human and non-human
animal models. The author presents a study of VNS effects on
anxiety and the capacity of atropine methyl nitrate to attenuate
these effects. The results indicate that VNS decreases anxiety in
the laboratory animals tested. These findings provide evidence to
support the testing and subsequent use of VNS therapy for the
treatment of clinical anxiety in humans. Because many therapies
that are effective in the treatment of depression effectively treat
anxiety, VNS therapy should be effective and approvable for
clinical anxiety. This book can serve as a research tool, training
mechanism, or surgical guide to the implantation of the vagus nerve
stimulating electrode in the laboratory rat. Hopefully, this
resource provides information that facilitates FDA approval of VNS
for treatment-resistant anxiety, a chronic, devastating and often
debilitating illness.
In 1997, Vagus Nerve Stimulation (VNS) therapy (Cyberonics,
Houston, Texas) was approved by the United States Food and Drug
Administration for the treatment of epilepsy refractory to
antiepileptic medications. In 2005, VNS received FDA approval for
treatment-resistant depression refractory to antidepressants, and
Cyberonics recently received FDA approval for the clinical study of
VNS for rapid cycling bipolar depression. Many researchers continue
to investigate the anxiolytic effects of VNS in human and non-human
animal models. The author presents a study of VNS effects on
anxiety and the capacity of atropine methyl nitrate to attenuate
these effects. The results indicate that VNS decreases anxiety in
the laboratory animals tested. These findings provide evidence to
support the testing and subsequent use of VNS therapy for the
treatment of clinical anxiety in humans. Because many therapies
that are effective in the treatment of depression effectively treat
anxiety, VNS therapy should be effective and approvable for
clinical anxiety. This book can serve as a research tool, training
mechanism, or surgical guide to the implantation of the vagus nerve
stimulating electrode in the laboratory rat. Hopefully, this
resource provides information that facilitates FDA approval of VNS
for treatment-resistant anxiety, a chronic, devastating and often
debilitating illness.
|
You may like...
Loot
Nadine Gordimer
Paperback
(2)
R398
R330
Discovery Miles 3 300
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.